Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
StemRIM rises for fourth straight session after completing patient enrollment in Phase 1/2 trial
Shares of StemRIM <4599> gained for a fourth consecutive session after the company announced the completed patient enrollment in a Phase 1/2 clinical trial for its out-licensed regenerative medicine candidate. The investigator-initiated trial of ledasemtide (HMGB1 peptide), licensed to Shionogi & Co Ltd <4507>, targets patients with ischemic cardiomyopathy. StemRIM noted the milestone will not impact its earnings guidance for the fiscal year ending July 2026.
Source: MINKABU PRESS
*Translated by generative AI. Click here for the original article.
Related Articles
RUNSYSTEM rebounds for the first time in three days as TSE lifts alert designation
FX summary: Dollar softens to 158.70 yen range on reports of ceasefire extension discussions
Yoshimura Food Holdings hits limit-down on weak scallop performance as FY Feb 2026 operating profit misses forecast
Market movers at 10 a.m.: 1,264 advancers vs 260 decliners
TO Books driving four growth strategies, including accelerated overseas expansion
HIOKI E.E. hits daily limit high on 28% Q1 operating profit growth
DAIKIN INDUSTRIES surges on report of Elliott stake
Gift Holdings extends gains as company boosts shareholder benefits
Bitcoin Japan shares jump to limit-up after TSE removes supervision designation
Living Tech shares jump after setting May 11 record date for 2-for-1 stock split